Psyched Wellnes Commences Antioxidant and Anti-Inflammatory Study on Muscimol

January 5, 2021
News

Toronto,Ontario, January 06, 2020 – Psyched Wellness Ltd.(formerly Duncan Park Holdings Corporation) (CSE:PSYC, OTCQB:DCNPF,FRANKFURT:5U9) (“Psyched”) a life sciences company focused on the production and distribution of artisanal functional andpsychedelic mushrooms, is pleased  to share that it has commenced a study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes via a nerve derived immunity and neuroprotective modulation models.

The study will be led by Brian Tancowny and will focus on determining the effectiveness of the active compound muscimol from the Amanita Muscaria mushroom for its potential dual antioxidant and anti-inflammatory properties. This preliminary work will focus on determining the potential role in health promotion via modulation of oxidative stress and inflammation. The mushroom, Amanita Muscaria naturally contain high levels of the active compound muscimol. This study will look at the potential neuroprotective effects of muscimol via neurotoxicity and immunomodulatory invitro cell - based models.

Antioxidants have been shown to reduce the risk of many diseases (including heart disease and certain cancers). Antioxidants can scavenge free radicals from the body cells and prevent or reduce the impact of the damage caused by oxidation. The protective effect of antioxidants continues to be studied around the world. Anti-inflammatory refers to the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs make up about half of analgesics, remedying pain by reducing inflammation as opposed to opioids, which affect the central nervous system to block pain signaling to the brain. Opioids have led to increased substance abuse by over prescribing and addictions.Muscimol if shown to have anti inflammatory properties may lead to a more effective natural therapeutic for treating many conditions.

 

“This initial preliminary study will provide more insight into the potential health and wellness properties of the active compound muscimol of the Amanita Muscaria mushroom, which may lead into advanced pre-clinical areas of study for further work into a natural therapeutic agent,”says Brian Tancowny.

Jeff Stevens, CEO of the Company says, “We are excited to explore the many potential uses of Muscimol, the active compound in Amanita Muscaria mushrooms. Our team continues to research new opportunities of this compound, and we look forward to providing insights into the new areas of focus soon.”  

 

Forfurther information, please contact:

 

Jeffrey Stevens

Chief Executive Officer

Psyched Wellness Ltd.

Tel: 647-400-8494

Email: jstevens@psyched-wellness.com

Website: http://www.psyched-wellness.com

 

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

 

About Psyched Wellness Ltd.:

 

Psyched Wellness Ltd. is a Canadian-based healthsupplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to createpremium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing aline of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

 

Cautionary Statement Regarding Forward Looking Information and Statements

 

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”,“estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Psyched Wellness Ltd. current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by Psyched at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information, including, without limitation,(i) the accuracy of the Toxicology Assessment, (ii) the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof, and (iii) the uses andpotential benefits of Amanita Muscaria. Given theserisks, uncertainties, and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in thispress release is made as of the date hereof, and Psyched is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Psyched Wellness Ltd.  management’s discussion and analysis for the six months ended May 31, 2020 and covering the subsequent period up to July 27,2020 (“MD&A”), dated July 27, 2020, which is available on Psyched WellnessLtd. profile at www.sedar.com.

 

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful priorto registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

 

This news release includes data that has been obtained from third party sources, including the findings from the Toxicology Assessment. The Company believes that the data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this news release or ascertained the underlying assumptions relied upon by such sources.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.